Clinical Trials Logo

Schizophrenia Prodrome clinical trials

View clinical trials related to Schizophrenia Prodrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00634361 Completed - Clinical trials for Schizophrenia Prodrome

Ethyl-EPA Treatment of Prodromal Patients

Start date: September 2001
Phase: Phase 2/Phase 3
Study type: Interventional

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

NCT ID: NCT00291226 Completed - Clinical trials for Schizophrenia Prodrome

Glycine vs Placebo for the Schizophrenia Prodrome

Start date: March 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.